Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling

Benjamin Y. Owusu, Namita Bansal, Phanindra K M Venukadasula, Larry J. Ross, Troy E. Messick, Sanjay Goel, Robert A. Galemmo, Lidija Klampfer

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The binding of hepatocyte growth factor (HGF) to its receptor MET activates a signaling cascade that promotes cell survival, proliferation, cell scattering, migration and invasion of malignant cells. HGF is secreted by cancer cells or by tumor-associated fibroblasts as pro-HGF, an inactive precursor. A key step in the regulation of HGF/MET signaling is proteolytic processing of pro-HGF to its active form by one of the three serine proteases, matriptase, hepsin or HGF activator (HGFA). We developed SRI 31215, a small molecule that acts as a triplex inhibitor of matriptase, hepsin and HGFA and mimics the activity of HAI-1/2, endogenous inhibitors of HGF activation. We demonstrated that SRI 31215 inhibits fibroblastinduced MET activation, epithelial-mesenchymal transition and migration of cancer cells. SRI 31215 overcomes primary resistance to cetuximab and gefitinib in HGFproducing colon cancer cells and prevents fibroblast-mediated resistance to EGFR inhibitors. Thus, SRI 31215 blocks signaling between cancer cells and fibroblasts and inhibits the tumor-promoting activity of cancer-associated fibroblasts. Aberrant HGF/MET signaling supports cell survival, proliferation, angiogenesis, invasion and metastatic spread of cancer cells, establishing HGF and MET as valid therapeutic targets. Our data demonstrate that inhibitors of HGF activation, such as SRI 31215, merit investigation as potential therapeutics in tumors that are addicted to HGF/MET signaling. The findings reported here also indicate that inhibitors of HGF activation overcome primary and acquired resistance to anti-EGFR therapy, providing a rationale for concurrent inhibition of EGFR and HGF to prevent therapeutic resistance and to improve the outcome of cancer patients.

Original languageEnglish (US)
Pages (from-to)29492-29506
Number of pages15
JournalOncotarget
Volume7
Issue number20
DOIs
StatePublished - May 17 2016

Fingerprint

Hepatocyte Growth Factor
Neoplasms
Cell Movement
Cell Survival
Fibroblasts
Cell Proliferation
pro-hepatocyte growth factor
Epithelial-Mesenchymal Transition
Serine Proteases
Therapeutics
Colonic Neoplasms

Keywords

  • Colon cancer
  • EGFR
  • HGF

ASJC Scopus subject areas

  • Oncology

Cite this

Owusu, B. Y., Bansal, N., Venukadasula, P. K. M., Ross, L. J., Messick, T. E., Goel, S., ... Klampfer, L. (2016). Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling. Oncotarget, 7(20), 29492-29506. https://doi.org/10.18632/oncotarget.8785

Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling. / Owusu, Benjamin Y.; Bansal, Namita; Venukadasula, Phanindra K M; Ross, Larry J.; Messick, Troy E.; Goel, Sanjay; Galemmo, Robert A.; Klampfer, Lidija.

In: Oncotarget, Vol. 7, No. 20, 17.05.2016, p. 29492-29506.

Research output: Contribution to journalArticle

Owusu, BY, Bansal, N, Venukadasula, PKM, Ross, LJ, Messick, TE, Goel, S, Galemmo, RA & Klampfer, L 2016, 'Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling', Oncotarget, vol. 7, no. 20, pp. 29492-29506. https://doi.org/10.18632/oncotarget.8785
Owusu, Benjamin Y. ; Bansal, Namita ; Venukadasula, Phanindra K M ; Ross, Larry J. ; Messick, Troy E. ; Goel, Sanjay ; Galemmo, Robert A. ; Klampfer, Lidija. / Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling. In: Oncotarget. 2016 ; Vol. 7, No. 20. pp. 29492-29506.
@article{b420c803ec52463cb083dc873859bfdd,
title = "Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling",
abstract = "The binding of hepatocyte growth factor (HGF) to its receptor MET activates a signaling cascade that promotes cell survival, proliferation, cell scattering, migration and invasion of malignant cells. HGF is secreted by cancer cells or by tumor-associated fibroblasts as pro-HGF, an inactive precursor. A key step in the regulation of HGF/MET signaling is proteolytic processing of pro-HGF to its active form by one of the three serine proteases, matriptase, hepsin or HGF activator (HGFA). We developed SRI 31215, a small molecule that acts as a triplex inhibitor of matriptase, hepsin and HGFA and mimics the activity of HAI-1/2, endogenous inhibitors of HGF activation. We demonstrated that SRI 31215 inhibits fibroblastinduced MET activation, epithelial-mesenchymal transition and migration of cancer cells. SRI 31215 overcomes primary resistance to cetuximab and gefitinib in HGFproducing colon cancer cells and prevents fibroblast-mediated resistance to EGFR inhibitors. Thus, SRI 31215 blocks signaling between cancer cells and fibroblasts and inhibits the tumor-promoting activity of cancer-associated fibroblasts. Aberrant HGF/MET signaling supports cell survival, proliferation, angiogenesis, invasion and metastatic spread of cancer cells, establishing HGF and MET as valid therapeutic targets. Our data demonstrate that inhibitors of HGF activation, such as SRI 31215, merit investigation as potential therapeutics in tumors that are addicted to HGF/MET signaling. The findings reported here also indicate that inhibitors of HGF activation overcome primary and acquired resistance to anti-EGFR therapy, providing a rationale for concurrent inhibition of EGFR and HGF to prevent therapeutic resistance and to improve the outcome of cancer patients.",
keywords = "Colon cancer, EGFR, HGF",
author = "Owusu, {Benjamin Y.} and Namita Bansal and Venukadasula, {Phanindra K M} and Ross, {Larry J.} and Messick, {Troy E.} and Sanjay Goel and Galemmo, {Robert A.} and Lidija Klampfer",
year = "2016",
month = "5",
day = "17",
doi = "10.18632/oncotarget.8785",
language = "English (US)",
volume = "7",
pages = "29492--29506",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "20",

}

TY - JOUR

T1 - Inhibition of pro-HGF activation by SRI31215, a novel approach to block oncogenic HGF/MET signaling

AU - Owusu, Benjamin Y.

AU - Bansal, Namita

AU - Venukadasula, Phanindra K M

AU - Ross, Larry J.

AU - Messick, Troy E.

AU - Goel, Sanjay

AU - Galemmo, Robert A.

AU - Klampfer, Lidija

PY - 2016/5/17

Y1 - 2016/5/17

N2 - The binding of hepatocyte growth factor (HGF) to its receptor MET activates a signaling cascade that promotes cell survival, proliferation, cell scattering, migration and invasion of malignant cells. HGF is secreted by cancer cells or by tumor-associated fibroblasts as pro-HGF, an inactive precursor. A key step in the regulation of HGF/MET signaling is proteolytic processing of pro-HGF to its active form by one of the three serine proteases, matriptase, hepsin or HGF activator (HGFA). We developed SRI 31215, a small molecule that acts as a triplex inhibitor of matriptase, hepsin and HGFA and mimics the activity of HAI-1/2, endogenous inhibitors of HGF activation. We demonstrated that SRI 31215 inhibits fibroblastinduced MET activation, epithelial-mesenchymal transition and migration of cancer cells. SRI 31215 overcomes primary resistance to cetuximab and gefitinib in HGFproducing colon cancer cells and prevents fibroblast-mediated resistance to EGFR inhibitors. Thus, SRI 31215 blocks signaling between cancer cells and fibroblasts and inhibits the tumor-promoting activity of cancer-associated fibroblasts. Aberrant HGF/MET signaling supports cell survival, proliferation, angiogenesis, invasion and metastatic spread of cancer cells, establishing HGF and MET as valid therapeutic targets. Our data demonstrate that inhibitors of HGF activation, such as SRI 31215, merit investigation as potential therapeutics in tumors that are addicted to HGF/MET signaling. The findings reported here also indicate that inhibitors of HGF activation overcome primary and acquired resistance to anti-EGFR therapy, providing a rationale for concurrent inhibition of EGFR and HGF to prevent therapeutic resistance and to improve the outcome of cancer patients.

AB - The binding of hepatocyte growth factor (HGF) to its receptor MET activates a signaling cascade that promotes cell survival, proliferation, cell scattering, migration and invasion of malignant cells. HGF is secreted by cancer cells or by tumor-associated fibroblasts as pro-HGF, an inactive precursor. A key step in the regulation of HGF/MET signaling is proteolytic processing of pro-HGF to its active form by one of the three serine proteases, matriptase, hepsin or HGF activator (HGFA). We developed SRI 31215, a small molecule that acts as a triplex inhibitor of matriptase, hepsin and HGFA and mimics the activity of HAI-1/2, endogenous inhibitors of HGF activation. We demonstrated that SRI 31215 inhibits fibroblastinduced MET activation, epithelial-mesenchymal transition and migration of cancer cells. SRI 31215 overcomes primary resistance to cetuximab and gefitinib in HGFproducing colon cancer cells and prevents fibroblast-mediated resistance to EGFR inhibitors. Thus, SRI 31215 blocks signaling between cancer cells and fibroblasts and inhibits the tumor-promoting activity of cancer-associated fibroblasts. Aberrant HGF/MET signaling supports cell survival, proliferation, angiogenesis, invasion and metastatic spread of cancer cells, establishing HGF and MET as valid therapeutic targets. Our data demonstrate that inhibitors of HGF activation, such as SRI 31215, merit investigation as potential therapeutics in tumors that are addicted to HGF/MET signaling. The findings reported here also indicate that inhibitors of HGF activation overcome primary and acquired resistance to anti-EGFR therapy, providing a rationale for concurrent inhibition of EGFR and HGF to prevent therapeutic resistance and to improve the outcome of cancer patients.

KW - Colon cancer

KW - EGFR

KW - HGF

UR - http://www.scopus.com/inward/record.url?scp=84969888715&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969888715&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.8785

DO - 10.18632/oncotarget.8785

M3 - Article

C2 - 27121052

AN - SCOPUS:84969888715

VL - 7

SP - 29492

EP - 29506

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 20

ER -